1. Home > Latest Topics >

Question 16: Cost-effectiveness of fluoroquinolones for AECB

20 June, 2018

question_16_6


LATEST TOPICS

Navigating antibiotic resistance in community-acquired pneumonia: Insights from Vietnam
29 October, 2024
Optimising antibiotic therapy: Insights on transitioning from intravenous to oral treatment for community-acquired pneumonia
27 September, 2024
Community-acquired pneumonia in Cambodia: Navigating the growing challenge of AMR
30 June, 2024
Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024

RELATED ARTICLES

Innovator versus Generic Antibiotics: Clinical Effectiveness in Pneumonia
23 October, 2023
Managing Urinary Tract Infection: Treatment Strategies in Japan
20 July, 2022
Management of Urinary Tract Infection with Sitafloxacin: Insights from Thailand
21 June, 2022
Under the new medical reform, there are challenges for the rational use of antibiotics, making it necessary to adopt coping strategies
20 April, 2023
Lower Respiratory Tract Infections: AECOPD, Aspiration, and Pneumonia in the COVID-19 Era (Chapter 5)
27 December, 2022